Case number 1:21-cv-01452
Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 5, 2023 | 76 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment)(nms) (Entered: 06/05/2023) (Main Document) (1) |
| Jun 5, 2023 | 76 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment)(nms) (Entered: 06/05/2023) (Consent Judgment) (6) |
| Jun 2, 2023 | 74 | REDACTED VERSION of 71 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/2/2023 (nms). (Entered: 06/02/2023) (6) |
| Jun 2, 2023 | 75 | REDACTED VERSION of 72 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/02/2023) (6) |
| May 30, 2023 | 72 | [SEALED] CONSENT JUDGMENT and Order of Injunction between Crystal Pharmaceutical (Suzhou) Co., Ltd. and Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 5/30/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01452-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 73 | NOTICE OF SERVICE of Responses and Objections to Novartis's Second Set of Common Interrogatories to Defendants filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 05/30/2023) (3) |
| May 26, 2023 | 71 | [SEALED] Proposed Consent Judgment and Order of Injunction between Plaintiff and Crystal Defendant, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/26/2023 (nms). (Entered: 05/26/2023) (0) |
| May 22, 2023 | 70 | NOTICE OF SERVICE of Novartis Objections and Responses to Defendants' Notice of Deposition to Plaintiff Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/22/2023) (5) |
| May 19, 2023 | 69 | NOTICE OF SERVICE of Defendants' Joint Supplemental Invalidity Contentions for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/19/2023) (3) |
| May 17, 2023 | 67 | NOTICE OF SERVICE of (1) Novartis's First Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9), (2) Novartis's Third Set of Interrogatories to Defendants (Nos. 5 & 6), and (3) Plaintiff Novartis's Supplemental Infringement Contentions Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/17/2023) (6) |
| May 17, 2023 | 68 | NOTICE OF SERVICE of Defendants' Third Set of Common Interrogatories (667 Patent) to Novartis (No. 14) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/17/2023) (3) |
| May 11, 2023 | 66 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Second Set of Common Interrogatories (Nos. 10-13), (2) Novartis's Objections and Responses to Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56), (3) Novartis's Supplemental Infringement Contentions Against Crystal Pharmaceutical (Suzhou) Co., Ltd., and (4) Novartis's Objections and Responses to Crystal's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/11/2023) (6) |
| May 9, 2023 | 64 | NOTICE of Deposition Under Fed. R. Civ. P. 30(B)(6) to Crystal Pharmaceutical (Suzhou) Co., Ltd. by Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 05/09/2023) (5) |
| May 9, 2023 | 65 | NOTICE OF SERVICE of Novartis's Requests for Admissions to Defendants to Establish the Authenticity of Documents or Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/09/2023) (6) |
| May 5, 2023 | 59 | NOTICE to Take Deposition of Adel Remond Rizkala on at a date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 60 | NOTICE to Take Deposition of Marcia Kayath on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 61 | NOTICE to Take Deposition of Victor Chengwei Shi on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 62 | NOTICE to Take Deposition of Fabian Chen on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 63 | NOTICE to Take Deposition of Plaintiff Novartis Pharmaceuticals Corporation on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (12) |
| Apr 26, 2023 | 58 | NOTICE OF SERVICE of (1) Novartis's Second Set of Common Interrogatories to Defendants and (2) Novartis's First Set of Requests for Admissions to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/26/2023) (6) |
| Apr 12, 2023 | 57 | ORAL ORDER: The agreed-upon constructius (see D.I. 66 in 22-cv-451-RGA; D.I. 56 in 21-cv-1452-RGA; D.I. 58 in 22-cv-498-RGA; D.I. 989 in 20-md-2930-RGA; D.I. 56 in 21-cv-1760-RGA; D.I. 55 in 21-cv-1794-RGA) are ACCEPTED. The Markman hearing scheduled for 4/14/2023, is CANCELED. Ordered by Judge Richard G. Andrews on 4/12/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/12/2023) (0) |
| Apr 11, 2023 | 54 | NOTICE OF SERVICE of Crystal's First Set of Individual Interrogatories (Nos. 1-3) to Plaintiff Novartis Pharmaceuticals Corporation [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 04/11/2023) (2) |
| Apr 11, 2023 | 55 | NOTICE OF SERVICE of copies of (i) Defendants' Second Set of Common Interrogatories to Novartis (Nos. 10-13); and, (ii) Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56) to Novartis filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 04/11/2023) (3) |
| Apr 11, 2023 | 56 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Markman hearing scheduled for 4/14/2023, regarding U.S. Patent No. 11,058,667. (Silver, Daniel) Modified on 4/12/2023 (nms). (Entered: 04/11/2023) (2) |
| Apr 7, 2023 | 53 | REDACTED VERSION of 49 Appendix, Volume 2, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/7/2023 (nms). (Entered: 04/07/2023) (20) |
| Apr 5, 2023 | 52 | MARKMAN HEARING ORDER: The Joint Claim Construction Brief (D.I. 974 ) is UNSEALED. The argument at the Markman Hearing on April 14, 2023, is limited to ten minutes per side. For the first disputed term, there appears to be a definition at '667 Patent 16:20-24. I think that is what each side means by their proposals. In any event, the parties' proposals are STRUCK. If either party thinks the above-referenced definition is inadequate in some regard, that party is to propose a construction including the definition and any additional language that the party argues is necessary. "Specific," as already proposed by Defendants, is rejected. I note that "crystalline," as proposed by Defendants, seems to be agreed upon by Novartis. (D.I. 974 at 31). But I am unclear whether it is necessary. Any proposed constructions should be submitted by 5 p.m. Tuesday, April 11, 2023. The proposed construction and any justification for it shall be set forth in 250 words or less. For the second disputed term, there also appears to be a definition, this time at '667 Patent 5:22-35. The parties only have one disagreement (in addition to the one addressed above in 3), which is Defendants' proposed negative limitation. As I understand Novartis's position, there is no dispute because part (a) of the definition includes exactly one "complex"-the one described at '667 Patent 16:20-24-and part (b) includes no complexes at all. If Novartis confirms that I understand its position correctly, then I also agree with Novartis that adding a negative limitation is pointless. Novartis should advise whether it confirms the above no later than 5 p.m. Tuesday, April 11, 2023. Signed by Judge Richard G. Andrews on 4/5/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/05/2023) (2) |
| Mar 31, 2023 | 47 | Joint Claim Construction Brief regarding U.S. Patent No. 11,058,667, filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/31/2023 (nms). Modified on 4/5/2023 (nms). (Entered: 03/31/2023) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 49 | [SEALED] APPENDIX, Volume 2 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits L-N)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (0) |
| Mar 31, 2023 | 50 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 51 | Joint Motion for Claim Construction - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/3/2023 (nms). (Entered: 03/31/2023) (8) |
| Mar 31, 2023 | 50 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit O-V) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 1) (16) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 1 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 2 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 3 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 4 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 5 of 5) (13) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit A-K) (30) |
| Mar 24, 2023 | 46 | NOTICE OF SERVICE of (i) Defendants' Sur-Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 with Exs. U and V [HIGHLY CONFIDENTIAL-ATTORNEYS EYES ONLY]; and, (ii) a replacement version of Ex. H, which was previously served on February 10, 2023 with Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/24/2023) (3) |
| Mar 22, 2023 | 45 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 6, 2023 | 43 | NOTICE OF SERVICE of Defendants' Objections and Responses to Novartis's First Set of Common Interrogatories (No. 1) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/06/2023) (5) |
| Mar 6, 2023 | 44 | NOTICE OF SERVICE of Novartis's Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/06/2023) (7) |
| Feb 10, 2023 | 42 | NOTICE OF SERVICE of Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 02/10/2023) (3) |
| Feb 2, 2023 | 41 | NOTICE OF SERVICE of Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/02/2023) (7) |
| Jan 23, 2023 | 40 | NOTICE OF SERVICE of Novartis's Opening Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/23/2023) (7) |
| Dec 30, 2022 | 39 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Main Document) (13) |
| Dec 30, 2022 | 39 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Appendix) (30) |
| Dec 15, 2022 | 37 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for Production (Nos. 1-44) for the '667 patent, and (2) Novartis's Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9) for the '667 patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 15, 2022 | 38 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Evidence for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 6, 2022 | 36 | STIPULATION TO EXTEND TIME the Deadline to Substantially Complete Document Production to January 18, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/06/2022) (7) |
| Nov 7, 2022 | 35 | NOTICE OF SERVICE of Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Responses to Novartis's Second Set of Interrogatories (No. 4) [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 11/07/2022) (2) |
| Oct 7, 2022 | 34 | NOTICE OF SERVICE of Novartis's Second Set of Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/07/2022) (10) |
| Sep 12, 2022 | 33 | NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Joint Initial Invalidity Contentions for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 09/12/2022) (2) |
| Sep 9, 2022 | 32 | NOTICE OF SERVICE of (i) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Responses to Novartis's First Set of Interrogatories (Nos. 1-3) [HIGHLY CONFIDENTIAL]; and, (ii) Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Responses to Novartis's First Set of Requests for Production of Documents and Things [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 09/09/2022) (2) |
| Sep 7, 2022 | 31 | NOTICE OF SERVICE of (1) Plaintiff's Rule 26(a)(1) Initial Disclosures, and (2) Plaintiff's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/07/2022) (14) |
| Sep 6, 2022 | 30 | NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Initial Disclosure Statement Pursuant to Fed. R. Civ. P. 26(a) and Paragraph 3 of the Delaware Default Standard for Discovery, including Electronically Stored Information filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 09/06/2022) (2) |
| Aug 29, 2022 | 29 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 08/29/2022) (21) |
| Aug 26, 2022 | 28 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/28/2022 (nms). (Entered: 08/26/2022) (21) |
| Aug 17, 2022 | 27 | Official Transcript of Rule 16 Conference held on 8/3/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/7/2022. Redacted Transcript Deadline set for 9/19/2022. Release of Transcript Restriction set for 11/15/2022. (Triozzi, Heather) (Entered: 08/17/2022) (29) |
| Aug 11, 2022 | 26 | NOTICE OF SERVICE of (1) Novartis's First Set of Requests to Defendants for the Production of Documents and Things and (2) Novartis's First Set of Interrogatories to Defendants (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/11/2022) (13) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 25, 2022 | 25 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Chart for U.S. Patent No. 11,058,667 and Plaintiff's First Supplemental Infringement Chart for U.S. Patent No. 11,096,918 against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 23 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 22 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 9, 2022 | 21 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 19 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 18 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 17 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 11, 2022 | 16 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 15 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 1, 2022 | 14 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 17, 2022 | 12 | Main Document (2) Docket Text: DECLARATION of Service of Crystal Pharmaceutical (Suzhou) Co., Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 4/8/2022 (nms). |
| Mar 17, 2022 | 12 | Exhibit A-B (7) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Dec 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Christina Schwarz and Nicholas N. Kallas for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01347-LPS, 1:21-cv-01452-LPS(srs) |
| Dec 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01347-LPS, 1:21-cv-01452-LPS(srs) |
| Nov 30, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (11 in 1:21-cv-01347-LPS, 11 in 1:21-cv-01452-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/30/21. Associated Cases: 1:21-cv-01347-LPS, 1:21-cv-01452-LPS (ntl) |
| Nov 17, 2021 | 11 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) |
| Nov 17, 2021 | 11 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a (4) |
| Nov 16, 2021 | 10 | Answer to Counterclaim (7) Docket Text: ANSWER to [7] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 4, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney C. Kyle Musgrove for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Nov 2, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Elizabeth M. Crompton for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Oct 29, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Scott A. Cunning, II for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Oct 27, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [9] MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove, and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP filed by Crystal Pharmaceutical (Suzhou) Co., Ltd. Signed by Judge Leonard P. Stark on 10/27/21. (ntl) |
| Oct 26, 2021 | 7 | Answer to Complaint (17) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Oct 26, 2021 | 8 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Crystal Pharmatech Co., Ltd. for Crystal Pharmaceutical (Suzhou) Co., Ltd. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| Oct 26, 2021 | 9 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove, and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| Oct 20, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (nms) |
| Oct 14, 2021 | 1 | Main Document (10) Docket Text: COMPLAINT filed against Crystal Pharmaceutical (Suzhou) Co., Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3721238.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(srs) |
| Oct 14, 2021 | 1 | Exhibit A (16) |
| Oct 14, 2021 | 1 | Civil Cover Sheet (2) |
| Oct 14, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Oct 14, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than 9/1/2021. Date of Expiration of Patent: 5/9/2036. Regulatory Stay Deadline: No Earlier than 7/7/2023. (srs) |
| Oct 14, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (srs) |
| Oct 14, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (srs) |
| Oct 14, 2021 | 6 | Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Crystal Pharmaceutical (Suzhou) Co., Ltd. on 10/14/2021. (srs) |
| Oct 14, 2021 | 1 | Complaint* (1) |
